SFRP1 Modulation via Site-Specific Disrupting Agents
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for alopecia, such as androgenic alopecia and alopecia areata, lack effective methods to modulate the expression of Secreted Frizzled Related Protein 1 (SFRP1), which is associated with hair growth regulation, leading to inadequate hair growth promotion or inhibition.
Innovation Solution
Development of site-specific SFRP1 disrupting agents that target the SFRP1 expression control region using polymeric molecules, polynucleotides, and fusion proteins to modulate SFRP1 expression, comprising DNA-binding domains of TALE or zinc finger proteins, and effector molecules like Cas or dCas polypeptides to specifically bind and alter the SFRP1 gene expression.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for alopecia are used, then general hair loss management is provided, but effective modulation of SFRP1 gene expression is not achieved
Solution Approach 1:
The invention divides the treatment approach into two distinct modules: (1) a targeting moiety that specifically recognizes and binds to the SFRP1 gene or its expression control region, and (2) an effector molecule that modulates gene expression. This segmentation allows each component to be optimized independently for its specific function, enabling reliable SFRP1 modulation while maintaining treatment versatility.
Solution Approach 2:
The effector molecule is designed to perform multiple functions: it can activate, repress, or knockdown SFRP1 gene expression depending on the specific effector used. This multi-functionality allows a single therapeutic platform to address different types of alopecia and various SFRP1 expression patterns, thereby improving both reliability and adaptability of the treatment.
2Measurement precision
If site-specific SFRP1 disrupting agents are developed, then specific modulation of SFRP1 expression is achieved, but treatment complexity increases
Solution Approach 1:
The invention introduces a mediator component - the targeting moiety - that acts as an intermediary between the therapeutic system and the SFRP1 gene. This targeting moiety specifically recognizes and binds to the SFRP1 gene or its control region, providing precise targeting without requiring direct complex interaction between the effector and the gene. This intermediary approach maintains high specificity while simplifying the overall agent design.
3Productivity
If SFRP1 expression is modulated to promote hair growth, then hair growth regulation is improved, but off-target effects may occur
Solution Approach 1:
The targeting moiety is designed with local quality - it specifically recognizes and binds only to unique sequences in the SFRP1 gene or its expression control region. This sequence-specific recognition ensures that the effector molecule acts only on the intended target, promoting hair growth through SFRP1 modulation while avoiding off-target effects on other genes or biological processes.
Data Source
AI summary
The present invention provides agents and compositions for modulating expression (e.g., enhanced or reduced expression) of a secreted frizzled related protein 1 (SFRP1) gene by targeting an SFRP1 expression control region and methods of use thereof for treating an SFRP1 associated disorder, e.g., hair loss.